A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)

Publisher： Karger

E-ISSN： 2235-3186|130|3|159-168

ISSN： 1660-8151

Source： Nephron, Vol.130, Iss.3, 2015-06, pp. : 159-168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effective Treatment of Idiopathic Membranous Nephropathy

By  

Nephron, Vol. 86, Iss. 4, 2000-12 ,pp. : 507-508

Karger

Access to resources Recommend Favorite

Antioxidative Treatment Retards Progression of Idiopathic Membranous Nephropathy

By  

Nephron, Vol. 86, Iss. 2, 2000-09 ,pp. : 208-209

Karger

Access to resources Recommend Favorite

Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal

By  

Nephron, Vol. 135, Iss. 1, 2016-09 ,pp. : 46-50

Karger

Access to resources Recommend Favorite

Rituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients

By  

Nephron Extra, Vol. 1, Iss. 1, 2011-12 ,pp. : 251-261

Karger

Access to resources Recommend Favorite

Endoplasmic Reticulum Stress Predicts Clinical Response to Cyclosporine Treatment in Primary Membranous Nephropathy

By  

American Journal of Nephrology, Vol. 43, Iss. 5, 2016-05 ,pp. : 348-356

Karger

Access to resources Recommend Favorite